EP3229900A1 - Onychomycosis treatment apparatus and method - Google Patents
Onychomycosis treatment apparatus and methodInfo
- Publication number
- EP3229900A1 EP3229900A1 EP15866415.1A EP15866415A EP3229900A1 EP 3229900 A1 EP3229900 A1 EP 3229900A1 EP 15866415 A EP15866415 A EP 15866415A EP 3229900 A1 EP3229900 A1 EP 3229900A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- plasma
- nail
- reactive
- gas
- perfluorocarbon liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 41
- 238000011282 treatment Methods 0.000 title claims description 49
- 208000010195 Onychomycosis Diseases 0.000 title abstract description 27
- 201000005882 tinea unguium Diseases 0.000 title abstract description 26
- 239000007789 gas Substances 0.000 claims abstract description 109
- 239000007788 liquid Substances 0.000 claims abstract description 68
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims abstract description 57
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000001301 oxygen Substances 0.000 claims abstract description 11
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000000460 chlorine Substances 0.000 claims abstract description 10
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 10
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 10
- 208000015181 infectious disease Diseases 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 244000052769 pathogen Species 0.000 claims description 9
- 230000004888 barrier function Effects 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- 230000000845 anti-microbial effect Effects 0.000 claims description 5
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims 3
- 208000026721 nail disease Diseases 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims 1
- 238000009616 inductively coupled plasma Methods 0.000 claims 1
- 239000007791 liquid phase Substances 0.000 claims 1
- 239000007843 reactive sulfur species Substances 0.000 claims 1
- 229950011087 perflunafene Drugs 0.000 abstract description 16
- UWEYRJFJVCLAGH-IJWZVTFUSA-N perfluorodecalin Chemical compound FC1(F)C(F)(F)C(F)(F)C(F)(F)[C@@]2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)[C@@]21F UWEYRJFJVCLAGH-IJWZVTFUSA-N 0.000 abstract description 16
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract description 7
- 229910052794 bromium Inorganic materials 0.000 abstract description 7
- 210000000282 nail Anatomy 0.000 description 44
- 239000000243 solution Substances 0.000 description 41
- 210000000003 hoof Anatomy 0.000 description 21
- 241000894007 species Species 0.000 description 15
- 241000233866 Fungi Species 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 230000000843 anti-fungal effect Effects 0.000 description 12
- 229940121375 antifungal agent Drugs 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 239000004599 antimicrobial Substances 0.000 description 8
- 238000009832 plasma treatment Methods 0.000 description 8
- 208000031888 Mycoses Diseases 0.000 description 7
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 7
- 210000004904 fingernail bed Anatomy 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- 206010017533 Fungal infection Diseases 0.000 description 6
- 239000003570 air Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 6
- 230000002538 fungal effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241001480043 Arthrodermataceae Species 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- -1 cyclic perfluoroamines Chemical class 0.000 description 5
- 230000037304 dermatophytes Effects 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000007845 reactive nitrogen species Substances 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000004906 toe nail Anatomy 0.000 description 5
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 4
- 230000001775 anti-pathogenic effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000005684 electric field Effects 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000004155 Chlorine dioxide Substances 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 3
- 241000223229 Trichophyton rubrum Species 0.000 description 3
- 235000019398 chlorine dioxide Nutrition 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000004905 finger nail Anatomy 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 2
- 206010034016 Paronychia Diseases 0.000 description 2
- 229920001774 Perfluoroether Polymers 0.000 description 2
- 241000223255 Scytalidium Species 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 241001459572 Trichophyton interdigitale Species 0.000 description 2
- 239000003633 blood substitute Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000000855 fungicidal effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000036562 nail growth Effects 0.000 description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 2
- ZJIJAJXFLBMLCK-UHFFFAOYSA-N perfluorohexane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F ZJIJAJXFLBMLCK-UHFFFAOYSA-N 0.000 description 2
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 238000006479 redox reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- LOJJTTDNNWYSGX-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4-nonafluoro-4-(1,1,2,2,3,3,4,4,4-nonafluorobutoxy)butane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)OC(F)(F)C(F)(F)C(F)(F)C(F)(F)F LOJJTTDNNWYSGX-UHFFFAOYSA-N 0.000 description 1
- OKIYQFLILPKULA-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4-nonafluoro-4-methoxybutane Chemical compound COC(F)(F)C(F)(F)C(F)(F)C(F)(F)F OKIYQFLILPKULA-UHFFFAOYSA-N 0.000 description 1
- CBEFDCMSEZEGCX-UHFFFAOYSA-N 1,1,2,2,2-pentafluoro-n,n-bis(1,1,2,2,2-pentafluoroethyl)ethanamine Chemical compound FC(F)(F)C(F)(F)N(C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)F CBEFDCMSEZEGCX-UHFFFAOYSA-N 0.000 description 1
- QIROQPWSJUXOJC-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6-undecafluoro-6-(trifluoromethyl)cyclohexane Chemical compound FC(F)(F)C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F QIROQPWSJUXOJC-UHFFFAOYSA-N 0.000 description 1
- VLTXBOGHSBHSAC-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,5,5,6-undecafluoro-6-[1,1,1,3,3,3-hexafluoro-2-(trifluoromethyl)propan-2-yl]cyclohexane Chemical compound FC(F)(F)C(C(F)(F)F)(C(F)(F)F)C1(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)F VLTXBOGHSBHSAC-UHFFFAOYSA-N 0.000 description 1
- DGLFZUBOMRZNQX-UHFFFAOYSA-N 1,1,2,2,3,3-hexafluorocyclobutane Chemical compound FC1(F)CC(F)(F)C1(F)F DGLFZUBOMRZNQX-UHFFFAOYSA-N 0.000 description 1
- HKCSZKHGTPOXKS-UHFFFAOYSA-N 2,2,3,3,4,4,5,5-octafluoro-1-(trifluoromethyl)pyrrolidine Chemical compound FC(F)(F)N1C(F)(F)C(F)(F)C(F)(F)C1(F)F HKCSZKHGTPOXKS-UHFFFAOYSA-N 0.000 description 1
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001480036 Epidermophyton floccosum Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 208000035450 Malformed Nails Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 206010061304 Nail infection Diseases 0.000 description 1
- 241000893976 Nannizzia gypsea Species 0.000 description 1
- 241001139967 Neoscytalidium Species 0.000 description 1
- 102100035411 Neuroglobin Human genes 0.000 description 1
- 108010026092 Neuroglobin Proteins 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010038848 Retinal detachment Diseases 0.000 description 1
- 229910018503 SF6 Inorganic materials 0.000 description 1
- 241000122799 Scopulariopsis Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 206010069363 Traumatic lung injury Diseases 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241000985906 Trichophyton soudanense Species 0.000 description 1
- 241001480048 Trichophyton tonsurans Species 0.000 description 1
- 241001480050 Trichophyton violaceum Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 108010062636 apomyoglobin Proteins 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 238000010891 electric arc Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- DVWNEKRVAURHBQ-UHFFFAOYSA-N fluoromethylcyclobutane Chemical class FCC1CCC1 DVWNEKRVAURHBQ-UHFFFAOYSA-N 0.000 description 1
- RBXBDCRAJKXJCQ-UHFFFAOYSA-N fluoromethylcycloheptane Chemical class FCC1CCCCCC1 RBXBDCRAJKXJCQ-UHFFFAOYSA-N 0.000 description 1
- YYKWXZYVDGWGSF-UHFFFAOYSA-N fluoromethylcyclopentane Chemical class FCC1CCCC1 YYKWXZYVDGWGSF-UHFFFAOYSA-N 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940104873 methyl perfluorobutyl ether Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 239000000615 nonconductor Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical class FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- UJMWVICAENGCRF-UHFFFAOYSA-N oxygen difluoride Chemical class FOF UJMWVICAENGCRF-UHFFFAOYSA-N 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 229960004692 perflenapent Drugs 0.000 description 1
- 229960004624 perflexane Drugs 0.000 description 1
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical class FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 description 1
- FYJQJMIEZVMYSD-UHFFFAOYSA-N perfluoro-2-butyltetrahydrofuran Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C1(F)OC(F)(F)C(F)(F)C1(F)F FYJQJMIEZVMYSD-UHFFFAOYSA-N 0.000 description 1
- LGUZHRODIJCVOC-UHFFFAOYSA-N perfluoroheptane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F LGUZHRODIJCVOC-UHFFFAOYSA-N 0.000 description 1
- YVBBRRALBYAZBM-UHFFFAOYSA-N perfluorooctane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F YVBBRRALBYAZBM-UHFFFAOYSA-N 0.000 description 1
- RVZRBWKZFJCCIB-UHFFFAOYSA-N perfluorotributylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F RVZRBWKZFJCCIB-UHFFFAOYSA-N 0.000 description 1
- AQZYBQIAUSKCCS-UHFFFAOYSA-N perfluorotripentylamine Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)N(C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F AQZYBQIAUSKCCS-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000004264 retinal detachment Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 1
- 229960000909 sulfur hexafluoride Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 208000009189 tinea favosa Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/04—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
- A61B18/042—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating using additional gas becoming plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/44—Applying ionised fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00452—Skin
- A61B2018/0047—Upper parts of the skin, e.g. skin peeling or treatment of wrinkles
Definitions
- the invention in one aspect relates generally to a system and method for the treatment of onychomycosis.
- Onychomycosis also known as " dermatophyte onychomycosis,” or “tinea unguium" is a fungal infection of the nail. It is the most common disease of the nails and constitutes about half of all nail abnormalities. This condition may affect toenails or fingernails, but toenail infections are particularly common. It occurs in about 10% of the adult population.
- the most common symptom of a fungal nail infection is the nail becoming thickened and discolored. As the infection progresses the nail can become brittle, with pieces breaking off or coming away from the toe or finger completely. If left untreated, the skin can become inflamed and painful underneath and around the nail. There may also be white or yellow patches on the nail bed or scaly skin next to the nail, and an odor may result. There is usually no pain or other bodily symptoms, unless the disease is severe. People with onychomycosis may experience significant psychosocial problems due to the appearance of the nail, particularly when fingers - which usually are always visible - rather than toenails are affected.
- Dermatophytids are fungus-free skin lesions that sometimes form as a result of a fungus infection in another part of the body. This could take the form of a rash or itch in an area of the body that is not infected with the fungus. Dermatophytids can be thought of as an allergic reaction to the fungus.
- the causative pathogens of onychomycosis include dermatophytes, Candida, and non-dermatophytic molds. Dermatophytes are the fungi most commonly responsible for onychomycosis in the temperate western countries; while Candida and nondermatophytic molds are more frequently involved in the tropics and subtropics with a hot and humid climate.
- Trichophyton rubrum is the most common dermatophyte involved in onychomycosis. Other dermatophytes that may be involved are T. interdigitale, Epidermophyton floccosum, T. violaceum, Microsporum gypseum, T. tonsurans, and T. soudanense. A common outdated name that may still be reported by is Trichophyton mentagrophytes for T. interdigitale . The name T mentagrophytes is now restricted to the agent of favus skin infection of the mouse; though this fungus may be transmitted from mice and their danders to humans, it generally infects skin and not nails.
- Candida and nondermatophytic molds in particular members of the mold generation Scytalidium (name recently changed to Neoscytalidium), Scopulariopsis, and Aspergillus.
- Candida mainly causes fingernail onychomycosis in people whose hands are often submerged in water.
- Scytalidium mainly affects people in the tropics, though it persists if they later move to areas of temperate climate.
- the present disclosure provides a system and method that includes delivery of a redox gas solution to treat onychomycosis, wherein the redox gas solution comprises a reactive species dissolved in a perfluorocarbon liquid.
- the reactive species may include, alone or in combination, one or more of reactive oxygen, reactive nitrogen, reactive chlorine, or reactive bromine species.
- the perfluorocarbon liquid may include perfluorodecalin.
- FIG. 1 is an illustration by flowchart of an exemplary method in accordance with the disclosure.
- FIG. 2 is a cross-sectional view of a portion of an exemplary system in accordance with the disclosure.
- FIG. 3A is a cross-sectional view of a container including an exemplary perfluorocarbon liquid in accordance with the disclosure.
- FIG. 3B is a cross-sectional view of a cap for the container shown in FIG. 3 A, the cap including an applicator for providing perfluorocarbon liquid to a nail/tissue.
- FIG. 3C is a perspective view of an exemplary application of perfluorocarbon liquid to nail/tissue using the applicator shown in FIG. 3B.
- FIG. 4 is a partial schematic view of an exemplary plasma generating device proximate nail/tissue to which a perfluorocarbon liquid has been applied in accordance with the disclosure.
- FIG 5A is a perspective view of an exemplary toe-clip applicator in accordance with the disclosure.
- FIG. 5B is a partial cross-sectional view of the exemplary toe-clip applicator shown in FIG. 5A.
- FIG. 6 is a perspective view of an alternate exemplary treatment system embodiment in accordance with the disclosure.
- the system provides delivery of a redox gas solution to treat onychomycosis, wherein the redox gas solution comprises a reactive species dissolved in a perfluorocarbon liquid.
- the perfluorocarbon liquid is applied at step 10 to the nail/tissue.
- a plasma gas is generated proximate the nail/tissue.
- the plasma gas forms reactive species that dissolve in the perfluorocarbon liquid to form a redox gas solution.
- the process may repeat or continue until sufficient redox gas solution is produced to eradicate nail/tissue fungus. See step 30.
- the reactive species may include, alone or in combination, one or more of reactive oxygen, reactive nitrogen, reactive chlorine, or reactive bromine species.
- the reactive species may be formed through use of a non-thermal plasma device, or otherwise be provided.
- a plasma 40 may be formed proximate a ground electrode 50.
- the plasma forms reactive species 60, 70.
- the reactive species 60, 70 dissolve in a perfluorocarbon liquid 80 applied to the surface 90 of nail/tissue 100.
- the redox gas solution including reactive species 60, 70 diffuses into the nail/tissue bed to eradicate fungus located therein.
- the plasma generating device includes a ground electrode 50.
- the device includes sufficiently high voltage pulses applied between two electrodes, one of which is the ground electrode 50, where at least one of the electrodes is insulated for plasma generation (not shown for clarity in Figure 2).
- the perfluorocarbon liquid may include perfluorodecalin.
- Perfluorodecalin and other suitable perfluorocarbon liquids have desirable wetting, gas absorption and diffusion properties.
- Perfluorocarbons PFCs
- fluorocarbons fluorocarbons
- perfluorochemicals liquids are formally derived from liquid hydrocarbons by replacing all the hydrogen atoms with fluorine atoms.
- This class of chemical compounds is characterized by its property to be extremely inert - chemically, biologically, and physiologically - due to the remarkable stability of the C-F bonds.
- the C-F bond is the strongest bond encountered in organic chemistry, and its strength is further increased when several fluorine atoms are present on the same carbon atom. The presence of fluorine even reinforces the strength of the C-C bonds.
- PFC liquids generally are clear, colorless, odorless, non-conducting, and nonflammable. They are approximately twice as dense as water, and generally are capable of dissolving large amounts of physiologically important gases. For their gas uptake function, PFCs act only as a carrier of the gasses and do not react with the gas or produce the gases. PFCs are generally very chemically stable compounds that are not metabolized in body tissues. They are physiologically inert as there is no enzyme system capable of modifying liquid PFCs, neither metabolically nor catabolically. Liquid PFCs are both hydrophobic and lipophobic, i.e., they are immiscible both with water and lipophilic liquids and generally form emulsions with them.
- PFCs are used in a variety of industries. They were first synthesized in the 1920s and developed for industry in the 1940s. PFCs are currently being used in retinal detachment surgery, liquid ventilation therapy for the lungs, as a blood substitute and as ultrasound and radiological imaging agents. They are used in both cosmetics and paints to facilitate easier product spreading and in textile manufacturing as a fabric protector.
- perfluorocarbon liquid or "PFC liquid” as used herein may include organic compounds in which all (or essentially all) of the hydrogen atoms are replaced with fluorine atoms.
- Representative perfluorinated liquids include cyclic and non-cyclic perfluoroalkanes, cyclic and non-cyclic perfluoroamines, cyclic and noncyclic perfluoroethers, cyclic and non-cyclic perfluoroaminoethers, and any mixtures thereof.
- perfluorinated liquids include the following: perfluoropentane, perfluorohexane, perfluoroheptane, perfluorooctane, perfluorodecalin, perfluoromethylcyclohexane, perfluorotributyl amine, perfluorotriamyl amine, perfluoro-N- methylmocpholine, perfluoro-Nethylmocpholine, perfluoroisopropyl mocpholine, perfluoro-N- methyl pyrrolidine, perfluoro- 1,2 is(trifluoromethyl)hexafluorocyclobutane, perfluoro-2- butyltetrahydrofuran, perfluorotriethylamine, perfluorodibutyl ether, and mixtures of these and other perfluorinated liquids.
- PFC at one atmosphere of pressure can carry 20 times more oxygen than saline will hold.
- PFCs are low viscosity surfactants that may lower the surface tension on the nail, so the PFC may spread uniformly and quickly over the nail structure. The low surface tension contributes to improved wetting of the surfaces.
- the surface tensions of PFCs are generally less than 20 dynes/cm and usually between 10 to 20 dynes/cm when measured at 25°C. When used in lung injury for ARDS patients, surface tension in the lung is noted to be 67 to 75 dynes/cm. In a lung with PFC, the surface tension is only 18 dynes/cm, which helps prevent alveolar collapse and reduces alveolar opening pressures.
- PFCs may displace water and circulate to those areas where gas exchange is diminished. PFCs also may wash out debris if the debris is lighter than the PFC used. PFCs are not taken up by the body and do not break down into toxic metabolites.
- Perfluorocarbon liquids may be compounds containing a high level of carbon-bound fluorine that are liquid at or below 106 °F. These fluorinated fluids may be capable of dissolving a substantial amount of a redox gas at operating conditions, typically in a temperature range from about 0 °C to about 50 °C.
- the perfluorocarbon liquid may be converted in whole or in part to a redox gas solution before topical application by dissolving the reactive gaseous species into perfluorocarbon liquid at the manufacturing facility and delivering the topical composition to the customer in a usable form such that the customer can apply the solution to the infected area as a treatment.
- PFC fluids may dissolve at least 500 mL of gaseous chlorine per 100 mL of fluid at 1 atm and 25 °C. In another exemplary embodiment, the PFC fluids may dissolve at least 1200 mL of gaseous chlorine at 1 atm and 25 °C.
- the oxidizing gas solutions used in the described methods may be saturated with a desired oxidizing gas. In another example, the concentration of ozone in the PFC may be greater than 1 ppm but less than 500 ppm.
- perfluorocarbons include, by way of example, perfluorocarbons such as fluoroheptanes, fluorocycloheptanes, fluoromethylcycloheptanes, fluorohexanes, fluorocyclohexanes, fluoropentanes, fluorocyclopentanes, fluoromethylcyclopentanes, fluorodimethylcyclopentanes, fluoromethylcyclobutanes, fluorodimethylcyclobutanes, fluorotrimethylcyclobutanes, fluorobutanes, fluorocyclobutanse, fluoropropanes, fluoroethers, fluoropolyethers, fluorotributylamines, fluorotriethylamines, perfluorohexanes, perfluoropentanes, perfluorobutanes, perfluoropropanes, sulfur hexafluoride, Methylperfluorobutylether (Graxafluor
- liquids may fulfill the mechanism of penetration enhancer / gas carrier and could concentrate the antifungal species from the plasma.
- alternative molecules that both concentrate and promote gas exchange may be used and include, but are not limited to, neuroglobin, apomyoglobin, hemoglobin, myoglobin, and synthetic blood or blood substitutes such as respirocytes.
- the perfluorocarbon or other liquid may include a co-solvent to improve as desired specific physical properties of the fluid.
- a semifluorinated alkane (SFA) that has a non-fluorinated hydrocarbon segment may be added to a PFC liquid.
- the liquid composition may comprise the combination of more than one PFC and/or more than one SFA. It may be useful to combine PFCs and SFAs, for example, to achieve a particular desired target property, such as a certain density, viscosity, lipophilicity or soluble capacity for a particular active ingredient such as a dye.
- the SFA may be essentially non-reactive with the redox gas.
- the SFA also may not reduce the solubility of the redox gas in the PFC.
- one or more useful SFAs may be selected from a group of SFAs including F 4 H 5 , F 4 H 6 , F H 8 , F 6 H 6 and F 6 H 8 .
- the perfluorocarbon liquid absorbs anti-pathogenic substances generated by a plasma-generating device. See, e.g., Figure 2.
- onychomycosis treatment is enhanced using a solution containing gaseous reactive oxygen or reactive nitrogen or reactive chlorine/bromine species that are dissolved in a perfluorocarbon liquid.
- redox gas solution a solution containing gaseous reactive oxygen or reactive nitrogen or reactive chlorine/bromine species dissolved in a perfluorocarbon liquid shall be referred to herein as a "redox gas solution.”
- an onychomycosis treatment system and method includes a topical composition to overcome one or more disadvantages of current topical fungal treatments.
- the topical composition may include a redox gas solution.
- a further exemplary embodiment provides a method of treating fungal infections like onychomycosis comprising contacting a skin or nail surface with a perfluorocarbon liquid, and converting at least a portion of the perfluorocarbon liquid into a redox gas solution.
- such method includes the step of dissolving a redox gas in a perfluorocarbon liquid proximate the site of a fungal infection like onychomycosis to be treated.
- the redox gas is formed during a non-thermal plasma treatment step.
- first and second treatment vectors for a fungal infection like onychomycosis are provided, wherein the first vector includes a redox gas formed as a result of a non-thermal plasma treatment step, and the second vector includes a redox gas solution.
- a plasma-generating device may create antimicrobial plasma species proximate a nail or skin area to be treated.
- antibacterial means tending to destroy microbes, prevent their development, or inhibit their pathogenic action, and includes reference to, without limitation, antibacterial and antifungal properties.
- Plasma is a gas-like phase of matter that typically contains many more reactive chemistry species than gas.
- a plasma-generating device turns electrical energy and a preselected gas (typically air, argon or helium) into electric fields, energetic electrons and favorable chemistry for antimicrobial therapy.
- a preselected gas typically air, argon or helium
- Non-thermal plasma gas at atmospheric pressure have been generated by microwave-induced plasma systems, dielectric barrier discharge (DBD), corona discharge, gliding arc discharge, and atmospheric pressure plasma jet.
- DBD dielectric barrier discharge
- corona discharge corona discharge
- gliding arc discharge and atmospheric pressure plasma jet.
- U.S. Patent No. 7,572,998 is hereby expressly incorporated by reference herein in its entirety for all purposes. The '998 patent describes some representative, but not exclusive, plasma generators that may be useful.
- the plasma-generating device 110 is electrically connected to both a power supply 120 and electrical control circuit to control both the duration and intensity of the plasma gas effluent 150.
- the electrical system may generate a high-voltage alternating current, typically between 2 to 20 kV at a frequency between 1 to 60 kHz.
- the power consumption may range from 0.05 W to 10.0 W.
- the high voltage electrode 130 may include a cylindrical copper block covered by a thin quartz plate 135 (e.g., approximately 1 mm in thickness).
- a stainless-steel woven wire mesh may be positioned next to the quartz plate 135 and used as the ground electrode 140.
- a wire diameter of 0.5 mm and mesh density of 8 ⁇ 8 meshes per cm 2 for example, may be used.
- a variation of the dielectric barrier discharge (DBD), the surface micro-discharge (SMD) may prove advantageous as the plasma-generating device in applications for igniting a stable plasma at ambient conditions.
- a SMD is a configuration of a DBD where the high voltage electrode is separated from a grounded electrode by a dielectric layer.
- the term dielectric barrier discharges may be used because current is forced through an electrical insulator (e.g., glass) to create a plasma.
- the charged particles may be confined to a plasma generation region around the grounded metal electrode.
- a SMD may be a desirable source of reactive chemical species for several reasons: the treated body part is electrically isolated from high-voltage electrode due to ground electrode; the discharges are non-thermal, increasing adjacent gas temperature slightly, e.g., by only a few degrees; devices can be scaled simply, e.g., by changing electrode size and input power; and the discharges may operate in ambient air, e.g., without requiring a noble gas mixture.
- SMD devices have been further described in a series of articles by Graves et al. and Morfill et al.
- ROS reactive oxygen species
- RNS reactive nitrogen species
- the active content of the plasma effluent at the treatment surface may include, for example, singlet oxygen (102), hydroxide (OH), hydrogen peroxide ( ⁇ 2 0 2 ), ozone (O 3 ), nitrous oxide (N 2 0), nitrogen dioxide (N0 2 ) and other excited molecules of air constituents that includes other reactive nitrogen and reactive oxygen species such as HN0 2 , NO 3 , HNO 3 and N 2 0 5 .
- Side reactions with these chemistries also may generate beneficial liquids and solids as the nail keratin and water in the nail can maintain antifungal properties long after the treatment is complete.
- Charged particles, electric fields and UV light also may be generated by plasma.
- the ionized gases generally last for very short periods of time (e.g., less than a second), but free radicals and reactive oxygen and nitrogen species that are electrically neutral may last long enough to be effective - perhaps up to many meters away from the source - in destroying fungus, bacteria and their spores. These free radicals denature critical lipid, protein and nucleic acid contents of the microbes, ultimately causing cell death. Research has demonstrated the effectiveness of plasma gas as well as nitrogen and oxygen free radicals such as ozone or hydrogen peroxide vapor or a combination of these in causing retarded fungal growth and fungal death.
- the byproduct of the plasma process is water (H 2 0) and carbon dioxide (C0 2 ).
- Kogelschatz and co-workers have performed early studies on the discharge characteristics and chemistry of air DBDs. More recently Y. Sakiyama et al. created a plasma chemistry model of a SMD device to determine the dynamics of the reactive neutral species it produces.
- the non-thermal plasma gas effluent may be directed to a treatment site in two ways: direct mode or indirect mode.
- Direct mode puts the treatment area within the visible plasma region discharge or plume, which may be between about 0.0 mm and about 5.0 mm for most devices.
- direct mode UV light, some charged particles and electric fields, in addition to reactive neutral species, may directly reach the treatment surface 160, to which a perfluorocarbon 170 may be applied.
- Indirect mode may have the treatment surface between about 5.0 mm and about 1.0 meter away. Thus, charged particles and electric field may have dissipated or decayed and may not reach the treatment surface.
- the indirect mode may benefit from a gas delivery system, wherein the plasma gas effluent may be directed to the treatment surface with tubing, inline fans, connectors, ports, etc. for input, delivery and output of antimicrobial agent to the treatment surface. That is, simple diffusion or forced air flow may promote delivery of reactive species to the nail bed, where the non-thermal plasma effluent or gas composition acts as an antimicrobial agent.
- Treatment may occur for a predetermined or desired period of time.
- the antimicrobial agent may be applied for a sufficient time to achieve an effective killing of all or a portion of the fungus within the nail structure.
- a sufficient time for application may be a time from about 10 seconds to about 4 hours.
- antimicrobial agent may be applied for a time from about 1 minute to about 15 minutes.
- antimicrobial agent may be applied for a time from about 5 minutes to about 20 minutes.
- antimicrobial agent may be applied for a time from about 30 minutes to about 1 hour.
- the application of antimicrobial agent may be cyclical in nature, wherein an electrical control circuit cycles the device on and off, e.g., for a predetermined period of time (for example a 50% duty cycle (1 minute on II minute off) for a 30 minute to 1 hour treatment period).
- a predetermined period of time for example a 50% duty cycle (1 minute on II minute off) for a 30 minute to 1 hour treatment period.
- redox gas solutions may include any gas capable of directly causing or actively triggering a reaction that eradicates pathogens within or on the surface of a material (e.g., skin or nail) where the gas is also readily soluble in a perfluorocarbon fluid.
- gases include, for example, methanethiol, bromine, chlorine, nitric oxide, ozone, chlorine dioxide, and/or sulfur dioxide.
- Reactive oxygen and reactive nitrogen species play a central role in oxidation-reduction biochemistry (also called redox biology) and are active in the immune response of both animals and plants.
- the reactive oxygen/nitrogen/chlorine/bromine or sulfur species listed in Table 1 may be useful in making redox gas solutions.
- Redox gases can be purchased in their gaseous form but, due to their relatively high vapor pressure, require expensive sealed and pressurized tanks for storage.
- redox reagents are often created in an aqueous solution such as hypochlorous acid (generated from sodium hypochlorite), hydrogen peroxide, or nitric acid.
- hypochlorous acid generated from sodium hypochlorite
- hydrogen peroxide or nitric acid.
- a redox gas may be added to a perfluorocarbon liquid by any conventional technique (e.g., sparging or gas injection or simple diffusion) to create a redox gas solution.
- Such redox gas solutions provide a means for delivering a stable solution of an oxidation or reduction gas in its most active, non- hydrolyzed state that also allows handling convenience and cost- effectiveness.
- Effective treatment of fungal nail infection may come from combining a redox gas with a perfluorocarbon liquid, then applying the redox gas solution topically, so that it penetrates the nail plate and inactivates pathogens residing in the nail bed.
- a method for treating nail fungus may comprise the steps of: preparing a redox gas solution and applying the redox gas solution to the infected nails.
- An applicator may be used to coat the infected nail.
- a redox gas solution 180 may include chlorine dioxide gas dissolved in perfluorodecalin to saturation and may be provided in a container 190 as a topical treatment for onychomycosis.
- the solution may have a minimum of 80 ppm chlorine dioxide as the treating agent.
- Treating an infected nail with the solution comprises using an applicator 200 (for example coupled to the cap 210 of container 190) to spread a coating 220 on and around the nail 230.
- an applicator 200 for example coupled to the cap 210 of container 190
- such application includes a series of successive treatments to improve the aesthetic appearance of the nail, destroy the fungal infection and promote healthy nail growth.
- the solution may be applied once a day for a minimum of sixty days to inactivate the fungus.
- the solution may be applied once a week to prevent fungus or fungal spores from reinfecting the nail matrix.
- a redox gas solution alternately may be generated at the skin or nail site by applying a perfluorocarbon liquid topically to the treatment area then treating the site with a redox gas, such as a gas created by a plasma-generating device. See Figures 2 and 4.
- a perfluorocarbon liquid may be administered immediately prior to treatment with a nonthermal plasma device in an amount sufficient to enhance the permeation of antifungal gas through and around the nail.
- the non-thermal plasma device allows the in-situ generation of gaseous reactive oxygen species and reactive nitrogen species that have antifungal properties.
- perfluorodecalin is pre-applied to the infected nail to act as a redox gas facilitator substance.
- a toe-clip 300 incorporating a plasma-generating device 320 is then attached to the infected toe and a 30-minute treatment protocol is initiated which generates antifungal gases 310 using electrical energy and air.
- This treatment may be performed as a series of successive treatments to improve the aesthetic appearance of the nail, destroy the fungal infection and promote healthy nail growth.
- the perfluorodecalin enhances the gas exchange between the nail bed and the plasma-generating device and allows the antifungal gas to more effectively penetrate the dense nail plate.
- a pre-made redox gas solution may be applied to a treatment area and additional treatment can be applied through the use of a non-thermal plasma treatment, thus replenishing or adding additional species of redox gas to the treatment area.
- a plasma-generating device 400 may include a chamber 410 having a lid or door 420, within which chamber a foot 430 may be placed for treatment proximate a plasma source 440.
- the plasma may be provided for a predetermined amount of time using a control circuit including a timer 450 that is activated by pressing a start/stop button or switch 460.
- the method includes coating the affected nail(s) along with the entire foot, in order to destroy pathogens thereon and help prevent reinfection of the nail by pathogens residing elsewhere on the foot.
- the redox gas solutions used during treatment may provide a means for delivering a stable solution of an oxidation or reduction gas in its most active, non- hydrolyzed state.
- the redox gas solutions may offer the advantage of providing a very low surface tension medium (generally on the order of approximately 15 dynes/cm), thereby enabling the oxidizing gas solution to efficiently contact and thoroughly penetrate a nail or skin infection.
- the PFC can act as a gas facilitator by providing an improvement in gas exchange between a non-thermal plasma device that creates in situ an antimicrobial gas and the nail barrier where the microbe resides.
- the PFC enhances the capacity of an active fungicidal gas to effectively penetrate the keratin matrix of fingernails and toenails such as to produce therapeutically relevant concentrations even in deeper regions of the matrix.
- PFD Perfluorodecalin
- the in vitro test model uses a bovine hoof disk, a surrogate nail model established in the literature. It is used along with a modified Franz-type diffusion cell to isolate the fungal contaminated side of the hoof in an enclosed chamber that ensures the treatment path is through the hoof barrier. An equal amount of T. rubrum is pipetted onto each hoof disc consisting of a lOOul suspension. Each hoof disk is then placed fungus side down into the modified Franz cell and sealed with an O-ring. Each hoof is then plasma treated for 45 minutes where the average thickness of hoof disks is 0.35mm. Eight hoof disks were treated as:
- each hoof went through a fungal collection protocol consisting of washing, dilution, plating and incubation.
- the results after seven days of incubation was a colony count of about 24,000,000 from the control hoof plate.
- the two hoofs that were treated with PFD-only had colony reductions of 7% and 28% compared to control.
- the two hoofs that were treated with 45 minutes of plasma only had colony reductions of 84% and 88%) when compared to control and quite unexpectedly the three hoofs that were treated with both PFD and 45 minutes of plasma treatment showed a colony reduction of 94% for one hoof and no colonies or 100%) and 100%) reductions for the other two hoofs.
- the contacting of the infected area with the perfluorocarbon can occur by various means.
- the perfluorocarbon can be applied with a dropper, foam tip swab, a cotton tip swab or a sponge applicator. It may be sprayed or squeezed on in a foam or gel formulation.
- a further apparatus for contacting the infected area with a perfluorocarbon consist of a gas-permeable membrane that includes perfluorocarbon liquid in its composition and allows for the rapid, enhanced and uniform transfer of plasma reactive species between the plasma device and the infection.
- the contacting of the infection with the perfluorocarbon membrane may define the treatment site.
- the gas permeable membrane composition comprises at least one material selected from ceramics, polymers, woven substrates, non-woven substrates, polyamide, polyester, polyurethane, fluorocarbon polymers, polyethylene, polypropylene, polyvinyl alcohol, polystyrene, vinyl, plastics, metals, alloys, minerals, non-metallic minerals, wood, fibers, cloth, glass, and hydrogels.
- the membrane barrier is a silicone composition that contains an effective amount of perfluorocarbon and acts as a dressing.
- the membrane may be manufactured in a toe or finger cot shape that may be slipped easily over the infected digit.
- a PFC may be loaded with antifungal gas in a manufacturing facility.
- a home-use device may be provided so that a patient may "load" the PFC at their home, then apply it to their toenails.
- the loading can be done with a plasma device, and/or a pure gas canister (NO, ozone, H 2 0 2 , etc.), etc. before treatment application by the patient at home.
- a pure gas canister NO, ozone, H 2 0 2 , etc.
- a secondary chemical reaction may create the gas.
- Redox gases can be purchased in their gaseous form but have relatively high vapor pressure, require expensive sealed and pressurized tanks for storage.
- redox reagents are often created in an aqueous solution such as hypochlorous acid (generated from sodium hypochlorite), hydrogen peroxide, or nitric acid.
- hypochlorous acid generated from sodium hypochlorite
- hydrogen peroxide or nitric acid.
- a redox gas may be added to a perfluorocarbon liquid by any conventional technique (e.g., sparging or gas injection or simple diffusion) to create a redox gas solution.
- redox gas solutions provide a means for delivering a stable solution of an oxidation or reduction gas in its most active, non- hydrolyzed state that also allows handling convenience and cost-effectiveness. Sterilization and Other Therapies
- Use of the described system and method also may promote wound sterilization and healing, may treat ear infections, may improve the sterilization of medical devices, may treat dental infections, may treat acne and various other dermatological infections, may promote bleeding cessation, may improve hand disinfection hygiene, or may treat skin, esophagus or colon cancer. It can also be used in veterinarian animal health for all such described applications.
- a method of sterilizing or decontaminating an item comprises the steps of: (a) coating the item to be sterilized with a perfluorocarbon liquid layer to allow the perfluorocarbon liquid to come in close proximity with the item; (b) generating a gaseous plasma around the item, such that both the liquid perfluorocarbon and the exterior of item is exposed to reactive components of said plasma; and (c) maintaining the item in said plasma for a time period sufficient to allow the active sterilizing species generated from the plasma to effect sterilization and destroy any microorganisms present.
- decontamination of a liquid or gas may occur using a PFC including a reactive species.
- PFC including a reactive species. Examples include, without limitation, using the PFC/reactive species solution to eliminate microbes in blood with the aid of a dialysis machine, and to improve the sterilization of air using conventional methods.
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462089945P | 2014-12-10 | 2014-12-10 | |
PCT/US2015/064666 WO2016094497A1 (en) | 2014-12-10 | 2015-12-09 | Onychomycosis treatment apparatus and method |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3229900A1 true EP3229900A1 (en) | 2017-10-18 |
EP3229900A4 EP3229900A4 (en) | 2018-11-14 |
Family
ID=59422567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15866415.1A Withdrawn EP3229900A4 (en) | 2014-12-10 | 2015-12-09 | Onychomycosis treatment apparatus and method |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3229900A4 (en) |
CN (1) | CN106999717A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019077391A1 (en) * | 2017-10-18 | 2019-04-25 | Giovanni Barco | Process and apparatus for producing reactive species of oxygen and / or nitrogen in liquid solution or in gas form |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006226749B2 (en) * | 2005-03-23 | 2012-07-19 | Oculus Innovative Sciences, Inc. | Method of treating second and third degree burns using oxidative reductive potential water solution |
CA2632183A1 (en) * | 2005-08-25 | 2007-03-01 | Philip R. Houle | Treatment systems for delivery of sensitizer solutions |
US8535691B2 (en) * | 2006-02-16 | 2013-09-17 | Peach Technologies, LLC. | Perflurochemical treatment process and apparatus |
GB0614278D0 (en) * | 2006-07-19 | 2006-08-30 | Insense Ltd | Hydrogen peroxide delivery system |
SI23311A (en) * | 2010-03-19 | 2011-09-30 | Kemijski inštitut | Pharmaceutical combination of acetylsalicylic acid and antifungal substance for destroying or inhibition of growth and replication of fungi |
US20120039796A1 (en) * | 2010-08-15 | 2012-02-16 | Demetrios Markou | Novel method for creating, suspending and stabilizing electronically modified oxygen derivatives, along with creating, suspending and stabilizing electronically modified reaction intermediates, in a bio compatible fluorocarbon suspension, for the purpose of inducing a cascading immune response in mammalian patients |
US20140200506A1 (en) * | 2011-09-17 | 2014-07-17 | M.O.E. Medical Devices Llc | Systems, methods and machine readable programs for electric field and/or plasma-assisted onychomycosis treatment |
JP6124361B2 (en) * | 2011-09-17 | 2017-05-10 | モー メディカル デバイセス エルエルシーMoe Medical Devices LLC | System, method and machine readable program for electric field and / or plasma assisted onychomycosis treatment |
US20140213548A1 (en) * | 2013-01-27 | 2014-07-31 | New Jersey Institute Of Technology | System and method for hemostatic wound dressing |
WO2014143412A1 (en) * | 2013-03-13 | 2014-09-18 | Devicearm, Inc. | Method and apparatus for antimicrobial treatment |
-
2015
- 2015-12-09 EP EP15866415.1A patent/EP3229900A4/en not_active Withdrawn
- 2015-12-09 CN CN201580066992.0A patent/CN106999717A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN106999717A (en) | 2017-08-01 |
EP3229900A4 (en) | 2018-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10039782B2 (en) | Onychomycosis treatment apparatus and method | |
US10039723B2 (en) | Onychomycosis treatment system and method | |
US20170361078A1 (en) | Onychomycosis treatment system and method | |
Kojtari et al. | Chemistry for antimicrobial properties of water treated with non-equilibrium plasma | |
Kolb et al. | Cold DC-operated air plasma jet for the inactivation of infectious microorganisms | |
JP4388115B2 (en) | Ozone treatment device for acne disease | |
US20170216615A1 (en) | Plasma treatment of an infected nail or infected skin | |
JP2016519596A (en) | Methods and solutions for rapid sterilization or inactivation of spores | |
JPWO2011027542A1 (en) | Method and apparatus for supplying ions to liquid and sterilization method and apparatus | |
BRPI0609711B1 (en) | USE OF A WATER SOLUTION WITH OXIDATIVE REDUCING POTENTIAL (ORP) | |
US20170354616A1 (en) | Onychomycosis treatment system and method | |
Morent et al. | Inactivation of bacteria by non-thermal plasmas | |
Chen et al. | Cold atmospheric plasma (CAP) technology and applications | |
US10493263B2 (en) | Onychomycosis treatment system and method | |
US20170142962A1 (en) | Methods and solutions including additives and stabilizers for killing or deactivating spores | |
WO2018175327A1 (en) | Onychomycosis treatment system and method | |
EP3229900A1 (en) | Onychomycosis treatment apparatus and method | |
CN110538334B (en) | Plasma sterilization and anti-infection device based on argon and ethanol mixed gas | |
US20180000937A1 (en) | Onychomycosis treatment system and method | |
JP2001029440A (en) | Sterilizing/deodorizing method for repeatedly used medical instrument, clothing or the like | |
US20180008523A1 (en) | Onychomycosis treatment system and method | |
Kalghatgi et al. | Applications of non thermal atmospheric pressure plasma in medicine | |
Han | Review of major directions in non-equilibrium atmospheric plasma treatments in medical, biological, and bioengineering applications | |
JP2023528038A (en) | Low temperature cloth dielectric barrier discharge device | |
KR200441030Y1 (en) | Ozone Bandage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20170517 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20181017 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 33/20 20060101ALI20181011BHEP Ipc: A61B 18/00 20060101ALI20181011BHEP Ipc: A61K 33/04 20060101ALI20181011BHEP Ipc: A61N 1/00 20060101ALI20181011BHEP Ipc: A61N 1/44 20060101AFI20181011BHEP Ipc: A61K 33/00 20060101ALI20181011BHEP Ipc: H05H 1/00 20060101ALI20181011BHEP Ipc: A61K 31/02 20060101ALI20181011BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20190207 |